Xilio Therapeutics
Developing its proprietary technology to create a new class of ultra-potent IO therapies that are activated selectively within the tumor.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor | €0.0 | round |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor | €0.0 Valuation: €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
* | N/A | $50.0m | Post IPO Equity |
| Total Funding | 000k | ||
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | - | - | - | 296 % | 2 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | - | - | - | (899 %) | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | - | - | (918 %) | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | - | - | - | 650 % | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Xilio Therapeutics is a biotechnology company focused on developing tumor-activated immuno-oncology therapies designed to provide effective, tolerable, and durable treatment options for patients with solid tumors. The company leverages its proprietary platform technology to create a pipeline of novel molecules, including antibodies, cytokines, bispecifics, and cell engagers, that localize anti-tumor activity within the tumor microenvironment. Xilio's business model centers on research and development, aiming to transform cancer treatment by minimizing systemic side effects and maximizing therapeutic efficacy. The company primarily serves patients with solid tumors, operating in the oncology market. Revenue is generated through partnerships, licensing agreements, and potential future sales of approved therapies.
Keywords: tumor-activated, immuno-oncology, solid tumors, antibodies, cytokines, bispecifics, cell engagers, therapeutic index, tumor microenvironment, cancer treatment.